Century Therapeutics to Present at the AACR Annual Meeting 2023
March 15 2023 - 4:01PM
Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage
biotechnology company developing induced pluripotent stem cell
(iPSC)-derived cell therapies in immuno-oncology, today announced
that preclinical data from the Company’s iPSC-based cell therapy
platform will be presented in a poster at the American Association
for Cancer Research (AACR) Annual Meeting on Monday, April 17,
2023.
Details of the poster presentation are as follows:
Abstract Number: 2914Title:
iPSC-derived CAR-NK cell therapy: nominating clinical candidate
clones through integrated multi-functional analysisPoster
Board Number: 19Session Title: Natural
Killer and Natural Killer T Cell-based Cellular
TherapiesSession Date: Monday, April 17,
2023Session Time: 1:30 – 5:00 PM
ETPresenter: Michael Hall, PhD, Senior Scientist,
Computational Immunology, Century Therapeutics
Full abstracts are currently available through the AACR
conference website.
About Century TherapeuticsCentury Therapeutics,
Inc. (NASDAQ: IPSC) is a clinical-stage biotechnology company
harnessing the power of adult stem cells to develop curative cell
therapy products for cancer that we believe will allow us to
overcome the limitations of first-generation cell therapies. Our
genetically engineered, iPSC-derived iNK and iT cell product
candidates are designed to specifically target hematologic and
solid tumor cancers. We are leveraging our expertise in cellular
reprogramming, genetic engineering, and manufacturing to develop
therapies with the potential to overcome many of the challenges
inherent to cell therapy and provide a significant advantage over
existing cell therapy technologies. We believe our commitment to
developing off-the-shelf cell therapies will expand patient access
and provide an unparalleled opportunity to advance the course of
cancer care. For more information on Century Therapeutics please
visit https://www.centurytx.com/.
Century Therapeutics Forward-Looking
StatementThis press release contains forward-looking
statements within the meaning of, and made pursuant to the safe
harbor provisions of, The Private Securities Litigation Reform Act
of 1995. All statements contained in this press release, other than
statements of historical facts or statements that relate to present
facts or current conditions, including but not limited to,
statements regarding our clinical development plans and timelines,
are forward-looking statements. These statements involve known and
unknown risks, uncertainties and other important factors that may
cause our actual results, performance, or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. In some cases, you can identify forward-looking
statements by terms such as “may,” “might,” “will,” “should,”
“expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “forecast,” “potential” or “continue” or the negative of
these terms or other similar expressions. The forward-looking
statements in this press release are only predictions. We have
based these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control, including, among others: our ability to
successfully advance our current and future product candidates
through development activities, preclinical studies, and clinical
trials; our ability to obtain FDA acceptance for our future IND
submissions and commence clinical trials on expected timelines, or
at all; our reliance on the maintenance of certain key
collaborative relationships for the manufacturing and development
of our product candidates; the timing, scope and likelihood of
regulatory filings and approvals, including final regulatory
approval of our product candidates; the impact of the COVID-19
pandemic, geopolitical issues and inflation on our business and
operations, supply chain and labor force; the performance of third
parties in connection with the development of our product
candidates, including third parties conducting our future clinical
trials as well as third-party suppliers and manufacturers; our
ability to successfully commercialize our product candidates and
develop sales and marketing capabilities, if our product candidates
are approved; and our ability to maintain and successfully enforce
adequate intellectual property protection. These and other risks
and uncertainties are described more fully in the “Risk Factors”
section of our most recent filings with the Securities and Exchange
Commission and available at www.sec.gov. You should not rely on
these forward-looking statements as predictions of future events.
The events and circumstances reflected in our forward-looking
statements may not be achieved or occur, and actual results could
differ materially from those projected in the forward-looking
statements. Moreover, we operate in a dynamic industry and economy.
New risk factors and uncertainties may emerge from time to time,
and it is not possible for management to predict all risk factors
and uncertainties that we may face. Except as required by
applicable law, we do not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
For More Information: Company: Elizabeth
Krutoholow – investor.relations@centurytx.comInvestors/Media:
Melissa Forst/Maghan Meyers – century@argotpartners.com
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Apr 2023 to Apr 2024